Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

被引：211

作者：

Kontzias, Apostolos ^{[2
]}

Kotlyar, Alexander ^{[1
]}

Laurence, Arian ^{[1
]}

Changelian, Paul ^{[3
]}

O'Shea, John J. ^{[1
]}

机构：

[1] NIAMSD, Mol Immunol & Inflammat Branch, NIH, Bethesda, MD 20892 USA

[2] NIAMSD, Pediat Rheumatol Branch, NIH, Bethesda, MD 20892 USA

[3] Infin Pharmaceut, Cambridge, MA USA

来源：

CURRENT OPINION IN PHARMACOLOGY | 2012年 / 12卷 / 04期

关键词：

ACTIVE RHEUMATOID-ARTHRITIS; PROTEIN-TYROSINE KINASE; JAK INHIBITOR; TOFACITINIB CP-690,550; INADEQUATE RESPONSE; DOUBLE-BLIND; MYELOPROLIFERATIVE NEOPLASMS; T-CELLS; PLACEBO; IMATINIB;

D O I：

10.1016/j.coph.2012.06.008

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Cytokines are critical for normal cell growth and immunoregulation but also contribute to growth of malignant cells and drive immune-mediated disease. A large subset of immunoregulatory cytokines uses the type I and type II cytokine receptors and pharmacological targeting of these cytokines/cytokines receptors has proven to be efficacious in treating immune and inflammatory diseases. These receptors rely on Janus family of kinases (Jaks) for signal transduction. Recently the first Jak inhibitor (jakinib) has been approved by the FDA and a second has been recommended for approval. Many other Jakinibs are likely to follow and in this brief review, we will discuss the state-of-the art of this new class of pharmacological agents.

引用

页码：464 / 470

页数：7

共 65 条

[1]

[Anonymous], ANN RHEUM DIS S3

[2]

[Anonymous], 2010, ARTHRITIS RHEUM, DOI DOI 10.1002/ART.29936

[3]

Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia [J].

Blink, M. ;

Buitenkamp, T. D. ;

van den Heuvel-Eibrink, M. M. ;

Danen-van Oorschot, A. A. ;

de Haas, V. ;

Reinhardt, D. ;

Klusmann, J-H ;

Zimmermann, M. ;

Devidas, M. ;

Carroll, A. J. ;

Basso, G. ;

Pession, A. ;

Hasle, H. ;

Pieters, R. ;

Rabin, K. R. ;

Izraeli, S. ;

Zwaan, C. M. .

LEUKEMIA, 2011, 25 (08) :1365-1368

[4]

Molecular phylogeny within type I cytokines and their cognate receptors [J].

Boulay, JL ;

O'Shea, JJ ;

Paul, WE .

IMMUNITY, 2003, 19 (02) :159-163

[5]

Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis [J].

Boy, Mary G. ;

Wang, Cunshan ;

Wilkinson, Bethanie E. ;

Chow, Vincent Fung-Sing ;

Clucas, Alan T. ;

Krueger, James G. ;

Gaweco, Anderson S. ;

Zwillich, Samuel H. ;

Changelian, Paul S. ;

Chan, Gary .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 (09) :2299-2302

[6]

Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139

[7]

Human severe combined immunodeficiency: Genetic, phenotypic, and functional diversity in one hundred eight infants [J].

Buckley, RH ;

Schiff, RI ;

Schiff, SE ;

Markert, ML ;

Williams, LW ;

Harville, TO ;

Roberts, JL ;

Puck, JM .

JOURNAL OF PEDIATRICS, 1997, 130 (03) :378-387

[8]

Burmester Gerd-Reudiger BR, 2011, ARTHRITIS RHEUM S, V63, P288

[9]

Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor [J].

Changelian, PS ;

Flanagan, ME ;

Ball, DJ ;

Kent, CR ;

Magnuson, KS ;

Martin, WH ;

Rizzuti, BJ ;

Sawyer, PS ;

Perry, BD ;

Brissette, WH ;

McCurdy, SP ;

Kudlacz, EM ;

Conklyn, MJ ;

Elliott, EA ;

Koslov, ER ;

Fisher, MB ;

Strelevitz, TJ ;

Yoon, K ;

Whipple, DA ;

Sun, JM ;

Munchhof, MJ ;

Doty, JL ;

Casavant, JM ;

Blumenkopf, TA ;

Hines, M ;

Brown, MF ;

Lillie, BM ;

Subramanyam, C ;

Shang-Poa, C ;

Milici, AJ ;

Beckius, GE ;

Moyer, JD ;

Su, CY ;

Woodworth, TG ;

Gaweco, AS ;

Beals, CR ;

Littman, BH ;

Fisher, DA ;

Smith, JF ;

Zagouras, P ;

Magna, HA ;

Saltarelli, MJ ;

Johnson, KS ;

Nelms, LF ;

Des Etages, SG ;

Hayes, LS ;

Kawabata, TT ;

Finco-Kent, D ;

Baker, DL ;

Larson, M .

SCIENCE, 2003, 302 (5646) :875-878

[10]

The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+cell numbers in cynomolgus monkey blood following chronic oral dosing [J].

Conklyn, M ;

Andresen, C ;

Changelian, P ;

Kudlacz, E .

JOURNAL OF LEUKOCYTE BIOLOGY, 2004, 76 (06) :1248-1255

← 1 2 3 4 5 6 7 →